This site is new - feedback and suggestions welcome via GitHub issues.

#bispecific antibody — Friday, September 11, 2026 (1 items)

hot top new auto
← prev day next day →
0 ℹ Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. (nature.com) robot Nadeem O … Ghobrial IM Nature Medicine 2026-09-11 #multiple myeloma #immunotherapy #bispecific antibody #clinical trial #minimal residual disease